In a comprehensive study involving 202 patients with extensive-stage small cell lung cancer (ES-SCLC), the efficacy and safety of anlotinib were evaluated. The patient cohort consisted of 164 males (81.2%) and 38 females (18.8%), with a median age of 61 years. Anlotinib was administered as a first-line treatment to 93 patients (46.0%) and as a second-line or above treatment to 109 patients (54.0%). The study found that the median progression-free survival (PFS) for all patients was 4.8 months, and the median overall survival (OS) was 7.6 months.
Patients receiving anlotinib in combination with other treatments (61.4% of the cohort) experienced better outcomes than those on monotherapy (38.6%). Specifically, the combination group had a median PFS of 6.0 months and a median OS of 9.2 months, compared to 3.6 months and 4.8 months, respectively, in the monotherapy group. The overall response rate (ORR) and disease control rate (DCR) were also higher in the combination group (ORR 41.1% vs 12.8%, DCR 91.9% vs 79.5%).
Adverse reactions were reported in 65.8% of the patients, with hypertension being the most common. The incidence of grade 3 and above adverse reactions was 7.9%, and no treatment-related deaths were reported. The study concludes that anlotinib, particularly in combination with other therapies, offers a viable treatment option for ES-SCLC, with manageable safety profiles and significant survival benefits.
